Claro Advisors LLC Reduces Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Claro Advisors LLC reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 93.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 636 shares of the company's stock after selling 9,144 shares during the period. Claro Advisors LLC's holdings in IDEXX Laboratories were worth $263,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Clark & Stuart Inc bought a new stake in shares of IDEXX Laboratories in the fourth quarter worth about $312,000. Paragon Advisors LLC grew its position in shares of IDEXX Laboratories by 10.7% in the 4th quarter. Paragon Advisors LLC now owns 4,405 shares of the company's stock worth $1,821,000 after buying an additional 426 shares during the last quarter. Czech National Bank grew its position in shares of IDEXX Laboratories by 5.9% in the 4th quarter. Czech National Bank now owns 17,755 shares of the company's stock worth $7,341,000 after buying an additional 989 shares during the last quarter. ST Germain D J Co. Inc. increased its stake in shares of IDEXX Laboratories by 517.2% during the fourth quarter. ST Germain D J Co. Inc. now owns 179 shares of the company's stock valued at $74,000 after buying an additional 150 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in shares of IDEXX Laboratories by 0.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 29,751 shares of the company's stock valued at $12,300,000 after acquiring an additional 117 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Up 0.3 %

Shares of NASDAQ IDXX traded up $1.44 on Thursday, reaching $424.36. 60,240 shares of the company's stock traded hands, compared to its average volume of 496,899. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The business's 50 day simple moving average is $423.98 and its two-hundred day simple moving average is $458.99. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The company has a market cap of $34.75 billion, a price-to-earnings ratio of 40.92, a price-to-earnings-growth ratio of 3.52 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million for the quarter, compared to the consensus estimate of $980.32 million. During the same period in the previous year, the company posted $2.53 earnings per share. The company's revenue for the quarter was up 6.6% compared to the same quarter last year. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now directly owns 905 shares of the company's stock, valued at $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 2.18% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on IDXX. JPMorgan Chase & Co. reduced their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Stifel Nicolaus cut their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a research note on Thursday, October 10th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Barclays lowered their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a report on Monday, November 4th. Finally, Leerink Partners assumed coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an "outperform" rating and a $500.00 target price on the stock. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $539.63.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.